Company and Stock Identity

How Brainomix Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Treat the stroke product and the lung product as two separate purchases, because different people judge them on different proof. Boehringer Ingelheim selected e-Lung as a co-primary endpoint in a Phase 3 trial, which is a different claim than a hospital deployment, and neither one carries over to the other product.

Brainomix Limited is a University of Oxford spinout, registered in England and Wales as company 07426406 with offices in Oxford. On February 24, 2026 the company said it extended its Series C financing to 25.4 million dollars, or 18.8 million pounds, with existing investors Parkwalk and Hostplus leading and US investor Modi Ventures joining. No ownership change was found as of October 10, 2026.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

No dated update is in the editorial file yet. Use the verified company sources below and check the profile verification date before relying on an older announcement.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Hiring runs through the company's own Workable job board, which describes Brainomix as an Oxford spinout building AI imaging software and lists its current openings there.

Qualification signal: Stroke pathway or respiratory trial experience is the real signal, because these products sit inside time-pressured treatment decisions and clinical trial endpoints rather than back-office workflow.

Check current roles at Brainomix. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources